The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas

Seminars in Diagnostic Pathology

Volumn 30, Issue 4, 2013, Pages 298-312

  Rossi, Giulio ^a,c   Graziano, Paolo ^b   Leone, Alvaro ^b   Migaldi, Mario ^c   Califano, Raffaele ^d,e  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ALK; EGFR; Immunohistochemistry; Lung; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE INHIBITOR; B RAF KINASE; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALK GENE; ARTICLE; BRAF GENE; CANCER CELL; CANCER CLASSIFICATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EGFR GENE; GENE MUTATION; HER2 GENE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PATIENT CARE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALK; ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE; BRAF; C-ROS ONCOGENE 1, RECEPTOR TYROSINE KINASE; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; HER2; IMMUNOHISTOCHEMISTRY; KRAS; LUNG; NSCLC; ROS1; V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG; V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890148104     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2013.11.007     Document Type: Article

References (143)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
3. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
4. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
5. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
6. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
7. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
8. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
9. Lee D.H., Park K., Kim J.H., et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16(4):1307-1314.
10. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
11. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
12. Keedy V.L., Temin S., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29(15):2121-2127.
13. D'Addario G., Früh M., Reck M., et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v116-v1199.
14. Yang J.C., Schuler M.H., Yamamoto N., et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012, 30. [suppl; abstr LBA7500].
15. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
16. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
17. Forbes S., Clements J., Dawson E., et al. Cosmic 2005. Br J Cancer 2006, 94(2):318-322.
18. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6(2):201-205.
19. Giaccone G., Gallegos Ruiz M., Le Chevalier T., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006, 12(20):6049-6055.
20. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25(7):760-766.
21. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
22. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2(1):e17.
23. Massarelli E., Varella-Garcia M., Tang X., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10):2890-2896.
24. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9(10):962-972.
25. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2006, 353(2):123-132.
26. Khambata-Ford S., Harbison C.T., Hart L.L., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(6):918-927.
27. O'Byrne K.J., Gatzemeier U., Bondarenko I., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12(8):795-805.
28. Adjei A.A., Mauer A., Bruzek L., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21(9):1760-1766.
29. Evans TL, Fidias P, Skarin A. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2 (13); 2002.
30. Kim E.S., Kies M.S., Fossella F.V., et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005, 104(3):561-569.
31. Sequist L.V., von Pawel J., Garmey E.G., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29(24):3307-3315.
32. Pao W., Iafrate J.A., Su Z. Genetically informed lung cancer medicine. J Pathol 2011, 223(2):230-240.
33. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
34. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
35. Travis W.D., Brambilla E., Noguchi M., et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
36. Brambilla E. Lung cancer: multidisciplinary approach for management. Eur Respir J 2010, 35(4):717-720.
37. Rekhtman N., Paik P.K., Arcila M.E., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18(4):1167-1176.
38. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23(4):57-65.
39. Marchetti A., Felicioni L., Malatesta S., et al. Clinical features and outcome of patients with nonsmall-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011, 29(26):3574-3579.
40. Bergethon K., Shaw A.T., Ou S.H.I., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30(8):863-870.
41. Perez-Moreno P., Brambilla E., Roman Thomas, Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18(9):1-9.
42. Chaft J.E., Arcila M.E., Paik P.K., et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012, 11(2):485-491.
43. Shim H.S., Lee D.H., Park E.J., Kim S.H. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011, 135(10):1329-1334.
44. Ding L., Getz G., Wheeler D.A., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
45. Motoi N., Szoke J., Riely G.J., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32(6):810-827.
46. Miller V.A., Riely G.J., Zakowski M.F., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26(9):1472-1478.
47. Sartori G., Cavazza A., Sgambato A., et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 2009, 131(4):478-489.
48. Kakegawa S., Shimizu K., Sugano M., et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 2011, 117(18):4257-4266.
49. Suda K., Tomizawa K., Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29(1):49-60.
50. Aviel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8(1):30-38.
51. Marchetti A., Buttitta F., Pellegrini S., et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996, 179(3):254-259.
52. Naoki K., Chen T.H., Richards W.G., et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62(23):7001-7003.
53. Buttitta F., Barassi F., Fresu G., et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006, 119(11):2586-2591.
54. Inamura K., Takeuchi K., Togashi Y., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3(1):13-17.
55. Rodig S.J., Mino-Kenudson M., Dacic S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16):5216-5223.
56. Yoshida A., Tsuta K., Nakamura H., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35(8):1226-1234.
57. Yoshida A., Tsuta K., Watanabe S., et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011, 72(3):309-315.
58. Yousem S.A., Nikiforova M., Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008, 32(9):1317-1321.
59. Paik P.K., Arcila M.E., Fara M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29(15):2046-2051.
60. De Oliveira Duarte Achcar R., Nikiforova M.N., Yousem S.A. Micropapillary lung adenocarcinoma: EGFR, KRAS, and BRAF mutational profile. Am J Clin Pathol 2009, 131(5):694-700.
61. Tomizawa K., Suda K., Onozato R., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancer. Lung Cancer 2011, 74(1):139-144.
62. Kim Y.H., Ishii G., Goto K., et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004, 10(21):7311-7317.
63. Yousem S.A. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod Pathol 2012, 25(Suppl 1):S11-S17.
64. Yatabe Y., Koga T., Mitsudomi T., et al. CK20 expression, CDX2 expression, K-ras mutations, and goblet cell morphology in a subset of lung adenocarcinoma. J Pathol 2004, 203(2):645-652.
65. Finberg K.E., Sequist L.V., Joshi V.A., et al. Mucinous differentiation correlates with absence of EGFR mutations and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007, 9(3):320-326.
66. Yatabe Y., Kosaka T., Takahashi T., et al. Epidermal growth factor receptor mutation is specific for terminal respiratory type adenocarcinoma. Am J Surg Pathol 2005, 29(15):633-639.
67. Rekhtman N., Ang D.C., Sima C.S., Travis W.D., Moreira A.L. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011, 24(10):1348-1359.
68. Mukhopadhyay S., Katzenstein A.L. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011, 35(1):15-25.
69. Righi L., Graziano P., Fornari A., et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117(15):3416-3423.
70. Pelosi G., Fabbri A., Bianchi F., et al. D (delta)Np63 (p40) and thyroid transcription factor-1 (TTF1) immunoreactivity upon small biopsies or cell blocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012, 7(2):281-290.
71. Bishop J.A., Teruya-Feldstein J., Westra W.H., Pelosi G., Travis W.D., Rekhtman N. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2011, 25(3):405-415.
72. Travis W.D. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012, 25(Suppl 1):S18-S30.
73. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma of the lung. Arch Pathol Lab Med 2008, 132:384-396.
74. Travis W.D., Rekhtman N. Pathologic diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32(1):22-31.
75. Travis W.D. Pathology of lung cancer. Clin Chest Med 2011, 32(4):669-692.
76. Neal J.W. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010, 15(1):3-5.
77. Matoso A., Singh K., Jacob R., et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 2010, 18(2):142-149.
78. Sun J.M., Han J., Ahn S., Park K., Ahn M.J. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011, 6(8):1392-1399.
79. Tatematsu A., Shimizu J., Murakami Y., et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14(19):6092-6096.
80. Fukui T., Tsuta K., Furuta K., et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 2007, 98(11):1714-1719.
81. Zakowski M.F., Ladanyi M., Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355(2):213-215.
82. Leone A., Graziano P., Gasbarra R., et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2011, 128(3):732-735.
83. Shukuya T., Takahashi T., Kaira R., et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harbouring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011, 102(5):1032-1037.
84. Marchetti A., Felicioni L., Buttitta F. Assessing EGFR mutations. N Engl J Med 2006, 354(5):526-528.
85. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005, 353(2):133-144.
86. Lebanony D., Benjamin H., Gilad S., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27(12):2030-2037.
87. Bishop J.A., Benjamin H., Cholakh H., et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010, 16(2):610-619.
88. Del Vescovo V., Cantaloni C., Cucino A., et al. miR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011, 35(2):268-275.
89. Barbareschi M., Cantaloni C., Del Vescovo V., et al. Heterogeneity of large cell carcinoma of the lung. An immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011, 136(5):773-782.
90. Hasanovic A., Ang D., Moreira A.L., Zakowski M.F. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012, 77(2):299-305.
91. Tsai T.H., Wu S.G., Chang Y.L., et al. Effusion immunohistochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012, 7(6):993-1000.
92. Ambrosini-Spaltro A., Campanini N., Bortesi B., et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol 2012, 20(4):356-362.
93. Yu J., Kane S., Wu J., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028.
94. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176.
95. Ilie M.I., Hofman V., Bonnetaud C., et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010, 457(4):483-495.
96. Kato Y., Peled N., Wynes M.W., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5(10):1551-1558.
97. Kawahara A., Azuma K., Sumi A., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011, 74(1):35-40.
98. Kawahara A., Yamamoto C., Nakashima K., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16(12):3163-3170.
99. Kitamura A., Hosoda W., Sasaki E., Mitsudomi T., Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16(13):3349-3355.
100. Kozu Y., Tsuta K., Kohno T., et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011, 73(1):45-50.
101. Nakamura H., Mochizuki A., Shinmyo T., et al. Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res 2010, 30(12):5233-5237.
102. Simonetti S., Molina M.A., Queralt C., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 8(Dec 18):135.
103. Wu S.G., Chang Y.L., Lin J.W., et al. Including total EGFR staining in scoring improves EGFR mutations detected by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011, 6(8):e23303.
104. Thunnissen E., Kerr K.M., Herth F.J.F., et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012, 76(1):1-18.
105. Azuma K., Okamoto I., Kawahara A., et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012, 7(1):122-127.
106. Garrido P., de Castro J., Concha A., et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 2012, 14(5):338-349.
107. Yi E.S., Boland J.M., Maleszewski J.J., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6(3):459-465.
108. Yang P., Kulig K., Boland J.M., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7(1):90-97.
109. Paik J.H., Choe G., Kim H., Choe J.Y., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6(8):466-472.
110. McLeer-Florin A., Moro-Sibilot D., Melis A., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7(2):348-354.
111. Mino-Kenudson M., Mark E.J. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med 2011, 135(5):655-664.
112. Murakami Y., Mitsudomi T., Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012, 2(Mar 16):1-9.
113. Koperek O., Kornauth C., Capper D., et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36(6):844-850.
114. Rimkunas V.M., Crosby K.E., Kelly M.E., et al. Analysis of receptor tyrosine kinase ROS1 positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012, 18(16):444-457.
115. Girard N., Deshpande C., Azzoli C.G., et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal lung relationship among multiple lung adenocarcinomas. Comparison with clinical guidelines. Chest 2010, 137(1):46-52.
116. Mattsson J.S., Imgenberg-Kreuz J., Edlund K., Botling J., Micke P. Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology 2012, 61(4):744-748.
117. Varella-Garcia M., Xavier A.C., et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008, 13(3):192-200.
118. Taniguchi K., Okami J., Kodama K., Higashiyama M., Kato K. Intratumour heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 95(5):929-935.
119. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011, 29(22):2972-2977.
120. Marchetti A., Milella A., Felicioni L., et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11(10):1084-1092.
121. Kuo Y.W., Wu S.G., Ho C.C., Shih J.Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(12):2039.
122. Tiseo M., Gelsomino F., Boggiani D., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71(2):241-243.
123. Popat S., Vieira de Araújo A., Min T., et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6(11):1962.
124. Lee J.K., Kim T.M., Koh Y., et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harbouring EGFR mutation and ALK translocation. Lung Cancer 2012, 77(2):460-463.
125. Dias-Santagata Akhavanfard S., David S.D., et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010, 2(5):146-158.
126. Sequist L.V., Heist R.S., Shaw A.T., et al. Implementing multiplex genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011, 22(12):2616-2624.
127. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
128. Edwards S.L., Roberts C., McKean M.E., Cockburn J.S., Jeffrey R.R., Kerr K.M. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000, 53(7):537-540.
129. Stinchcombe T.E., Grilley-Olson J.E., Socinski M.A. If histology matters. . .. J Clin Oncol 2010, 11(11):1810-1812.
130. West H., Harpole D., Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009, 136(4):1112-1118.
131. Rossi G., Papotti M., Barbareschi M., Graziano P., Pelosi G. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 2009, 27(28):e141-e142.
132. Nizzoli R., Tiseo M., Gelsomino F., et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011, 6(3):489-493.
133. Nathan N.A., Narayan E., Smith M.M., Horn M.J. Cell block cytology. Improved preparation and its efficacy in diagnostic cytology. Am J Clin Pathol 2000, 114(4):599-606.
134. Rekhtman N., Brandt S.M., Sigel C.S., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6(4):451-458.
135. Chowdhuri S.R., Xi L., Pham T.H., et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012, 25(4):548-555.
136. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012.
137. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012, 13(4):252-266.
138. Pallis A., Briasoulis E., Linardou H., et al. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011, 18(11):1613-1628.
139. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci 2007, 104(52):20932-20937.
140. Sasaki T., Koivunen J., Ogino A., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060.
141. Ellison G., Donald E., McWalter G., et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 6(29):132.
142. Akbari M., Hansen M.D., Halgunset J., Skorpen F., Krokan H.E. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 2005, 7(1):36-39.
143. Williams C., Pontén F., Moberg C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999, 155(2):1467-1471.